Abstract
Inflammatory bowel disease (IBD) is known as a chronic inflammation of gastrointestinal tract that its pathogenesis still is not completely understood. Several drug categories are used for management of IBD but there is no exact cure for the disease, however biological drugs targeting the inflammation of gut are on the center of attention. In investigating the anti-inflammatory drugs, phosphodiesterase inhibitors were found to be effective in different inflammatory disorders. Of them phosphodiesterase 4 (PDE4) inhibitors are considered for treatment of asthma and chronic obstructive pulmonary disease (COPD). Some of the PDE4 inhibitors showed promising efficacy in animal studies, however to date no phase III clinical study showed their effectiveness in IBD. The present study has the most relevant studies in this field. PDE4 inhibitors affect IBD in different ways including anti-inflammatory, anti-depressant, and anti-fibrotic effects. Unfortunately, the most common side effect of PDE4 inhibitors is nausea which limits its use. Tetomilast the second generation of PDE4 inhibitors showed promising effects in phase II studies with better safety profile. Other drugs in this class are ongoing phase II and III trials.
Keywords: Inflammatory bowel disease, phosphodiesterase 4 inhibitor, Crohn's disease, ulcerative colitis, Phosphodiesterase 4 Inhibitors, chronic inflammation, gastrointestinal tract, IBD, phosphodiesterase inhibitors, asthma, chronic obstructive pulmonary disease, Tetomilast, incontinence, abdominal pain, reactive oxygen metabolites, aminosalicylates, immunomodulators, Phosphodiesterase enzyme, neurodegeneration, immunomodulatory cells, NO synthesis, anti-TNF- antibody, hepatic fibrosis, growth factor-I, cyclic adenosine monophosphate, cyclic guanosine monophosphate, protein kinases, phosphorylation, rheumatoid arthritis, multiple sclerosis, endotoxin, Sildenafil, a PDE5 inhibitor, Roflumilast, rolipram, cilomilast, T-cell chemotaxis, isoenzymes
Current Pharmaceutical Design
Title: Phosphodiesterase 4 Inhibitors in Inflammatory Bowel Disease: A Comprehensive Review
Volume: 16 Issue: 33
Author(s): Pooneh Salari-Sharif and Mohammad Abdollahi
Affiliation:
Keywords: Inflammatory bowel disease, phosphodiesterase 4 inhibitor, Crohn's disease, ulcerative colitis, Phosphodiesterase 4 Inhibitors, chronic inflammation, gastrointestinal tract, IBD, phosphodiesterase inhibitors, asthma, chronic obstructive pulmonary disease, Tetomilast, incontinence, abdominal pain, reactive oxygen metabolites, aminosalicylates, immunomodulators, Phosphodiesterase enzyme, neurodegeneration, immunomodulatory cells, NO synthesis, anti-TNF- antibody, hepatic fibrosis, growth factor-I, cyclic adenosine monophosphate, cyclic guanosine monophosphate, protein kinases, phosphorylation, rheumatoid arthritis, multiple sclerosis, endotoxin, Sildenafil, a PDE5 inhibitor, Roflumilast, rolipram, cilomilast, T-cell chemotaxis, isoenzymes
Abstract: Inflammatory bowel disease (IBD) is known as a chronic inflammation of gastrointestinal tract that its pathogenesis still is not completely understood. Several drug categories are used for management of IBD but there is no exact cure for the disease, however biological drugs targeting the inflammation of gut are on the center of attention. In investigating the anti-inflammatory drugs, phosphodiesterase inhibitors were found to be effective in different inflammatory disorders. Of them phosphodiesterase 4 (PDE4) inhibitors are considered for treatment of asthma and chronic obstructive pulmonary disease (COPD). Some of the PDE4 inhibitors showed promising efficacy in animal studies, however to date no phase III clinical study showed their effectiveness in IBD. The present study has the most relevant studies in this field. PDE4 inhibitors affect IBD in different ways including anti-inflammatory, anti-depressant, and anti-fibrotic effects. Unfortunately, the most common side effect of PDE4 inhibitors is nausea which limits its use. Tetomilast the second generation of PDE4 inhibitors showed promising effects in phase II studies with better safety profile. Other drugs in this class are ongoing phase II and III trials.
Export Options
About this article
Cite this article as:
Salari-Sharif Pooneh and Abdollahi Mohammad, Phosphodiesterase 4 Inhibitors in Inflammatory Bowel Disease: A Comprehensive Review, Current Pharmaceutical Design 2010; 16 (33) . https://dx.doi.org/10.2174/138161210794079209
DOI https://dx.doi.org/10.2174/138161210794079209 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fc Receptors as Potential Targets for the Treatment of Allergy, Autoimmune Disease and Cancer
Current Drug Targets - Immune, Endocrine & Metabolic Disorders YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer’s Disease
Current Neuropharmacology Systemic Approach to the Study of Complex Bone Disorders at the Whole- Genome Level
Current Genomics Novel Asthma Therapies: A Review
Current Drug Therapy In Vitro Evaluation of Reversible and Time-Dependent Inhibitory Effects of Kalanchoe crenata on CYP2C19 and CYP3A4 Activities
Drug Metabolism Letters Household Typology and Family Social Capital Among White British and Pakistani Women in Bradford, England
Current Women`s Health Reviews An Overview on Sources, Biosynthesis and Bioactivities of Osthole: A Potential Bioactive Compound
Current Bioactive Compounds On the Cellular and Molecular Regulatory Transcriptional Mechanisms and Responsive Putative Pathways to Inflammatory Oxidative Stress Revisited: Current Immunological Breakthroughs and Views at a Glance
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Pharmacological Approaches in an Experimental Model of Non-Small Cell Lung Cancer: Effects on Tumor Biology
Current Pharmaceutical Design An Update on Herbal Anti-inflammatory Agents in Periodontal Therapy
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Pharmacometrics of Stilbenes: Seguing Towards the Clinic
Current Clinical Pharmacology Zanthoxylum: A Review of its Traditional Uses, Naturally Occurring Constituents and Pharmacological Properties
Current Organic Chemistry Modified-Release Solid Formulations for Colonic Delivery
Recent Patents on Drug Delivery & Formulation MIF and the Genetic Basis of Macrophage Responsiveness
Current Immunology Reviews (Discontinued) Therapeutic Antibodies
Drug Design Reviews - Online (Discontinued) Tachykinins and Tachykinin Receptors: Structure and Activity Relationships
Current Medicinal Chemistry Cytokine Antibody Arrays in Biomarker Discovery and Validation
Current Proteomics Utility and Limitations of SP600125, an Inhibitor of Stress-Responsive c-Jun N-Terminal Kinase
Current Enzyme Inhibition Neuroimmune Aspects of Sjogren`s Syndrome: Role of VIP/VPAC System in Immune and Salivary Gland Epithelial Cell Function
Current Pharmaceutical Design Colorectal Carcinogensis and Suppression of Tumor Development by Inhibition of Enzymes and Molecular Targets
Current Enzyme Inhibition